Association of Monocyte Chemoattractant Protein‐1 (<i>MCP‐1</i>)‐2518A&gt;G Polymorphism with Susceptibility to Coronary Artery Disease: A Meta‐Analysis

Bai, Xiaoyan; Li, Shujing; Wang, Miao; Qu, Xiaoni; Hu, Gaolei; Xu, Zhaowei; Chen, Min; He, Guo‐Wei; Wu, Harry X.

doi:10.1111/ahg.12105

Cited by 9 publications

(7 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of 17q25.3-rs6465657C allele was calculated in the control group of each study. 25 The prevalence rates of the C allele obtained from the individual studies were pooled together in the overall population or in various ethnic populations using the random-effects model when heterogeneity existed.…”

Section: Methodsmentioning

confidence: 99%

“…In case of heterogeneity, meta-regression analysis was performed to determine the source of heterogeneity. The year of publication, the ethnicity (Caucasian, Asian, or African-American), source of controls, genotyping method, and sample size (defined as sample size less than 500 cases, or more than 500 cases) were chosen as common variables which might be correlated to heterogeneity, 25 , 29 assessed by meta regression, and P <0.05 was considered to be statistical difference.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Association between 17q25.3-rs6465657 polymorphism and prostate cancer susceptibility: a meta-analysis based on 19 studies

Jiang¹,

Zhang

Bai

et al. 2016

OTT

Self Cite

View full text Add to dashboard Cite

BackgroundGenome-wide association studies have identified rs6465657 polymorphism at chromosome 17q25.3 as a new prostate cancer (PCa) susceptibility locus in people of European descent. However, subsequent replication studies have yielded inconsistent results among different ethnicities. In this study, a comprehensive meta-analysis was conducted to systematically evaluate the relationship between rs6465657 polymorphism and PCa risk.MethodsAll the articles involved were identified from PubMed, EMBASE, Web of Science, EBSCO databases, and Google Scholar before December 2015. The odds ratios (ORs) with corresponding 95% confidence internals (95% CIs) were pooled under the allele model. Fourteen eligible articles with 19 studies were finally included.ResultsIn the overall population, the 17q25.3-rs6465657C allele was found to be significantly associated with increased risk of PCa compared to the T allele (OR =1.097; 95% CI: 1.061–1.134; P<0.001). In the subgroup analysis stratified by ethnicity, significantly increased risk was found in the Caucasian population (OR =1.120; 95% CI: 1.078–1.162; P<0.001), while the difference of OR did not reach the statistical significance in the Asian or African-American population. The analyses of sensitivity indicated the robust stability of the results, and the Begg’s and Egger’s test indicated that no publication bias existed.ConclusionThe current meta-analysis suggested that the 17q25.3-rs6465657 polymorphism could be associated with PCa susceptibility, especially in the Caucasians, while this association might be different in other ethnicities.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Association between 17q25.3-rs6465657 polymorphism and prostate cancer susceptibility: a meta-analysis based on 19 studies

Jiang¹,

Zhang

Bai

et al. 2016

OTT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Study-specific RR (OR) estimates with 95%CIs for the highest versus lowest categories of dietary vitamin C intake were pooled using Z-test under fixed-effects model (Mantel-Haenszel method) if no significant heterogeneity existed 18 . Otherwise, the random-effects model (DerSimonian-Laird method) was preferred.…”

Section: Methodsmentioning

confidence: 99%

Association between Dietary Vitamin C Intake and Risk of Prostate Cancer: A Meta-analysis Involving 103,658 Subjects

Bai¹,

Qu²,

Jiang³

et al. 2015

J. Cancer

Self Cite

View full text Add to dashboard Cite

We attempted to systematically determine the association between dietary intake of vitamin C and risk of prostate cancer. PubMed and Embase were searched to obtain eligible studies published before February 2015. Cohort or case-control studies that reported the relative risk (RR)/odds ratio (OR) estimates with 95% confidence intervals (CIs) for the association between vitamin C intake and prostate cancer risk were included. Eighteen studies regarding dietary vitamin C intake were finally obtained, with a total of 103,658 subjects. The pooled RR of prostate cancer for the highest versus the lowest categories of dietary vitamin C intake was 0.89 (95%CI: 0.83-0.94; p = 0.000) with evidence of a moderate heterogeneity (I2 = 39.4%, p = 0.045). Meta-regression analysis suggested that study design accounted for a major proportion of the heterogeneity. Stratifying the overall study according to study design yielded pooled RRs of 0.92 (95%CI: 0.86-0.99, p = 0.027) among cohort studies and 0.80 (95%CI: 0.71-0.89, p = 0.000) among case-control studies, with no heterogeneity in either subgroup. In the dose-response analysis, an inverse linear relationship between dietary vitamin C intake and prostate cancer risk was established, with a 150 mg/day dietary vitamin C intake conferred RRs of 0.91 (95%CI: 0.84-0.98, p = 0.018) in the overall studies, 0.95 (95%CI: 0.90-0.99, p = 0.039) in cohort studies, and 0.79 (95%CI: 0.69-0.91, p = 0.001) in case-control studies. In conclusion, intake of vitamin C from food was inversely associated with prostate cancer risk in this meta-analysis.

show abstract

“…Although tobacco use and lipid metabolism disorder are the classical risk factors for CAD, some studies have found that CAD shows strong familial aggregation, and a gene variant is also a key risk marker for CAD patients [ 3 , 4 ]. For example, Bai et al found that the monocyte chemoattractant protein-1 (MCP-1)-2518A>G polymorphism was associated with susceptibility to CAD, especially in Caucasians [ 5 ]. By contrast, Zhang et al found that the COX-2–765G>C (rs20417) polymorphism was protective against CAD [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Lipoprotein Lipase (LPL) Polymorphism and the Risk of Coronary Artery Disease: A Meta-Analysis

Xie

2017

IJERPH

View full text Add to dashboard Cite

Background: In recent years, the lipoprotein lipase (LPL) polymorphism has been extensively investigated as a potential risk factor for coronary artery disease (CAD). However, the results of these studies have been inconsistent. Therefore, we performed this meta-analysis to explore the association between LPL polymorphism and CAD risk. Methods: The literature was searched from electronic databases such as Embase, China Biological Medicine Database, PubMed, Knowledge Infrastructure, and China National Web of Science by the key words “coronary artery disease”, “lipoprotein lipase” and “polymorphism”. All of the studies included in this manuscript met the inclusion and exclusion criteria. An odds ratio (OR) analysis using a 95% confidence interval (CI) was employed to assess the association of the LPL polymorphism with CAD susceptibility. Results: We performed a meta-analysis of 14 case-control studies including HindIII, Ser447X and PvuII polymorphism. A statistically significant increase in the risk of CAD was associated with LPL HindIII polymorphism. This included HindIII H+H+ genotype (OR = 1.28, 95% CI = 1.09–1.49, p = 0.002, I2 = 43%) and H+ allele genotype (OR = 1.27, 95% CI = 1.03–1.58, p = 0.03, I2 = 67%). Ser447X XX genotype (OR = 2.37, 95% CI = 1.33–4.24, p = 0.004, I2 = 53%) was also associated with CAD risk. However, PvuII polymorphism was found to have no significant association with CAD risk. Conclusions: LPL HindIII polymorphism was significantly associated with the risk of CAD. For Ser447X polymorphism, it was found that only XX genotype was significantly associated with CAD risk. Furthermore, PvuII polymorphism had no significant association with CAD risk. It was considered that LPL HindIII polymorphism might serve as a potential biomarker for CAD risk.

show abstract

Association of Monocyte Chemoattractant Protein‐1 (MCP‐1)‐2518A>G Polymorphism with Susceptibility to Coronary Artery Disease: A Meta‐Analysis

Cited by 9 publications

References 54 publications

Association between 17q25.3-rs6465657 polymorphism and prostate cancer susceptibility: a meta-analysis based on 19 studies

Association between 17q25.3-rs6465657 polymorphism and prostate cancer susceptibility: a meta-analysis based on 19 studies

Association between Dietary Vitamin C Intake and Risk of Prostate Cancer: A Meta-analysis Involving 103,658 Subjects

Lipoprotein Lipase (LPL) Polymorphism and the Risk of Coronary Artery Disease: A Meta-Analysis

Contact Info

Product

Resources

About